Đang chuẩn bị liên kết để tải về tài liệu:
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
The two 52-week INPULSIS trials investigated nintedanib versus placebo in patients with IPF, FVC ≥50% predicted and DLco 30–79% predicted. The 24-week INSTAGE trial investigated nintedanib plus sildenafil versus nintedanib alone in patients with IPF and DLco ≤35% predicted. |